Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Retained Earnings: 2010-2025

Historic Retained Earnings for Arrowhead Pharmaceuticals (ARWR) over the last 16 years, with Sep 2025 value amounting to -$1.6 billion.

  • Arrowhead Pharmaceuticals' Retained Earnings fell 0.10% to -$1.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.6 billion, marking a year-over-year decrease of 0.10%. This contributed to the annual value of -$1.6 billion for FY2025, which is 0.10% down from last year.
  • Arrowhead Pharmaceuticals' Retained Earnings amounted to -$1.6 billion in FY2025, which was down 0.10% from -$1.6 billion recorded in FY2024.
  • In the past 5 years, Arrowhead Pharmaceuticals' Retained Earnings registered a high of -$644.7 million during FY2021, and its lowest value of -$1.6 billion during FY2025.
  • Over the past 3 years, Arrowhead Pharmaceuticals' median Retained Earnings value was -$1.6 billion (recorded in 2024), while the average stood at -$1.4 billion.
  • Data for Arrowhead Pharmaceuticals' Retained Earnings shows a maximum YoY crashed of 58.43% (in 2024) over the last 5 years.
  • Over the past 5 years, Arrowhead Pharmaceuticals' Retained Earnings (Yearly) stood at -$644.7 million in 2021, then fell by 27.31% to -$820.8 million in 2022, then dropped by 25.01% to -$1.0 billion in 2023, then tumbled by 58.43% to -$1.6 billion in 2024, then declined by 0.10% to -$1.6 billion in 2025.